Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | F7 | P08709 | 3/20 | 0.38 |
| ▸ | F3 | P13726 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611678 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL1551787 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL17798928 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL10910041 | 1.00 | — | — | |
| SCHEMBL3387971 | 1.00 | — | — | |
| SCHEMBL21679678 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL21679677 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL21484057 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL21484058 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL1611679 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP19A1PPARGOXER1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254658-B1 | REMEDIES FOR THE TREATMENT OF NERVE DIORDERS | TAKARA BIO INC (JP) | 2008-09-24 | — | — | EP | disclosed |
| US-7268160-B2 | Remedies | TAKARA BIO, INC. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20030144316-A1 | Remedies | TAKARA BIO INC. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1254658-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144316-A1 | Remedies | NGF, BDNF, NTRK2 | ALDH1A1 2063/4885CYP19A1 3455/4885PPARG 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.